机器人
“We’re not doing 30 bets a year”: Vijay Pande on b
AI导读
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared dat...
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
内容声明
本文内容基于公开市场信息与媒体报道进行整理，部分观点来自社区讨论。如涉及事实性问题，欢迎通过 xurj005@163.com 与我们指正，我们将及时核实并更新。
